Analyst Price Targets — AGIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 7, 2026 1:14 pm | — | Truist Financial | $41.00 | $42.07 | TheFly | Agios Pharmaceuticals price target raised to $41 from $36 at Truist |
| July 7, 2026 11:27 am | — | RBC Capital | $32.00 | $37.39 | TheFly | Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital |
| June 15, 2026 10:49 am | Emily Bodnar | H.C. Wainwright | $54.00 | $29.46 | StreetInsider | Agios Pharma (AGIO) PT Raised to $54 at H.C. Wainwright |
| April 30, 2026 11:35 am | — | Truist Financial | $36.00 | $28.05 | TheFly | Agios Pharmaceuticals price target lowered to $36 from $39 at Truist |
| April 20, 2026 4:07 pm | Emily Bodnar | H.C. Wainwright | $50.00 | $26.93 | TheFly | H.C. Wainwright cuts Agios target on smaller market post Novo data |
| February 12, 2026 4:40 pm | Greg Renza | Truist Financial | $39.00 | $28.42 | StreetInsider | Agios Pharma (AGIO) PT Raised to $39 at Truist Securities |
| December 26, 2025 11:26 am | — | Leerink Partners | $40.00 | $29.17 | TheFly | Agios Pharmaceuticals price target raised to $40 from $34 at Leerink |
| December 24, 2025 5:29 pm | — | H.C. Wainwright | $62.00 | $29.17 | TheFly | Agios Pharmaceuticals price target raised to $62 from $48 at H.C. Wainwright |
| December 24, 2025 4:55 pm | Gregory Renza | Truist Financial | $38.00 | $29.17 | TheFly | Agios Pharmaceuticals price target raised to $38 from $32 at Truist |
| November 24, 2025 12:25 pm | — | Truist Financial | $32.00 | $25.24 | TheFly | Agios Pharmaceuticals initiated with a Buy at Truist |
Latest News for AGIO
Agios stock surged after FDA granted priority review for mitapivat in sickle cell disease. Mitapivat showed mixed Phase 3 results, and competition is coming from Novo Nordisk.
Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sickle cell disease, with a decision due on Nov. 1, 2026.
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The company took a major step toward an accelerated approval of mitapivat in sickle cell disease today. Agios needs to complete a confirmatory trial before a full traditional approval can be granted.
Agios stock skyrocketed closer to a profit-taking zone Tuesday after the FDA assigned its sickle cell drug a speedy review.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AGIO.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.